ABL1 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

AFF1 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains AFF1 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

ALK is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains ALK status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) [3].

BCL2 is an inclusion eligibility criterion in 2 clinical trials for mature B-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain BCL2 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [3].

BCL6 is an inclusion eligibility criterion in 2 clinical trials for mature B-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain BCL6 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [3].

BCR is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains BCR status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

Chlorambucil and rituximab have evidence of efficacy in patients with BIRC3 mutation in mature B-cell lymphoma/leukemia [3].

Vemurafenib has evidence of efficacy in patients with BRAF mutation in mature B-cell lymphoma/leukemia [3].

CBFB is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains CBFB status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

Ibrutinib has evidence of efficacy in patients with CCND1 mutation in mature B-cell lymphoma/leukemia [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains DEK status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains ELL status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

Ibrutinib has evidence of efficacy in patients with IGH mutation in mature B-cell lymphoma/leukemia [3].

KIT is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains KIT status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains KMT2A status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

Chlorambucil and rituximab have evidence of efficacy in patients with MALT1 mutation in mature B-cell lymphoma/leukemia [3].

MECOM is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains MLF1 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains MLLT1 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains MLLT10 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains MLLT3 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains MLLT4 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MYC is an inclusion eligibility criterion in 3 clinical trials for mature B-cell lymphoma/leukemia, of which 1 is open and 2 are closed. Of the trials that contain MYC status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].

MYH11 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains NRIP3 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains NUP214 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains RPN1 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

RUNX1T1 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains RUNX1T1 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

TP53 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].